Shares of McKesson Co. (NYSE:MCK) have been assigned an average rating of “Hold” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $137.99.
MCK has been the subject of several research analyst reports. Barclays reaffirmed a “hold” rating and set a $124.00 price target on shares of McKesson in a research note on Sunday, January 6th. Zacks Investment Research downgraded shares of McKesson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Morgan Stanley decreased their price target on shares of McKesson from $142.00 to $130.00 and set an “equal weight” rating for the company in a research note on Monday, December 3rd. UBS Group initiated coverage on shares of McKesson in a research note on Thursday, January 17th. They set a “neutral” rating and a $134.00 price target for the company. Finally, ValuEngine downgraded shares of McKesson from a “sell” rating to a “strong sell” rating in a research note on Friday, March 1st.
Shares of McKesson stock traded down $1.62 on Friday, hitting $120.61. 7,979 shares of the company traded hands, compared to its average volume of 1,619,935. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.57 and a current ratio of 1.02. McKesson has a 52 week low of $106.11 and a 52 week high of $160.84. The company has a market capitalization of $23.14 billion, a PE ratio of 9.56, a P/E/G ratio of 1.26 and a beta of 1.25.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Investors of record on Friday, March 1st will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date is Thursday, February 28th. McKesson’s dividend payout ratio (DPR) is 12.36%.
In related news, EVP Lori A. Schechter sold 7,700 shares of the business’s stock in a transaction that occurred on Wednesday, January 16th. The shares were sold at an average price of $122.96, for a total value of $946,792.00. Following the completion of the transaction, the executive vice president now owns 10,000 shares of the company’s stock, valued at $1,229,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.87% of the company’s stock.
A number of large investors have recently modified their holdings of MCK. Standard Life Aberdeen plc grew its holdings in shares of McKesson by 16.7% during the fourth quarter. Standard Life Aberdeen plc now owns 288,482 shares of the company’s stock valued at $32,039,000 after buying an additional 41,289 shares during the last quarter. Northern Trust Corp raised its position in McKesson by 1.3% during the fourth quarter. Northern Trust Corp now owns 2,369,712 shares of the company’s stock valued at $261,783,000 after acquiring an additional 30,134 shares in the last quarter. Wedge Capital Management L L P NC raised its position in McKesson by 6.6% during the fourth quarter. Wedge Capital Management L L P NC now owns 273,751 shares of the company’s stock valued at $30,241,000 after acquiring an additional 17,003 shares in the last quarter. BlackRock Inc. raised its position in McKesson by 2.3% during the fourth quarter. BlackRock Inc. now owns 15,773,706 shares of the company’s stock valued at $1,742,522,000 after acquiring an additional 358,982 shares in the last quarter. Finally, Morgan Stanley raised its position in McKesson by 7.0% during the third quarter. Morgan Stanley now owns 664,384 shares of the company’s stock valued at $88,132,000 after acquiring an additional 43,589 shares in the last quarter. 83.11% of the stock is owned by institutional investors.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Recommended Story: Why do corrections happen?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.